Financhill
Back

ITeos Therapeutics Quote, Financials, Valuation and Earnings

ITeos Therapeutics Price Quote

$13.63

ITeos Therapeutics Key Stats

Sell
19
ITeos Therapeutics (ITOS) is a Sell

Day range:
$12.52 - $14.02
52-week range:
$12.52 - $35.64
Dividend yield:
0%
P/E ratio:
5.32
P/S ratio:
1.92
P/B ratio:
0.73%

Volume:
403K
Avg. volume:
261.7K
1-year change:
-57.75%
Market cap:
$486.9M
Revenue:
$267.6M
EPS:
$2.55

How Much Does ITeos Therapeutics Make?

Is ITeos Therapeutics Growing As A Company?

  • What Is ITeos Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.78%
  • What Is ITeos Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is -0.89%

ITeos Therapeutics Stock Price Performance

What Is ITeos Therapeutics 52-Week High & Low?

ITeos Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy ITeos Therapeutics?

Is ITeos Therapeutics Cash Flow Positive?

  • What Is ITOS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$111.2M
  • What Is ITeos Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $2M
  • What Is ITeos Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$446.1M

ITeos Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    ITOS return on invested capital is 15.52%
  • What Is ITeos Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 11.84%
  • What Is ITOS Return On Equity?
    ROE is a measure of profitability and is 15.52%

ITeos Therapeutics Earnings Date & Stock Price

ITeos Therapeutics Competitors

  • Who Are ITeos Therapeutics's Competitors?
    Below is a list of companies who compete with ITeos Therapeutics or are related in some way:
    • Chimerix Inc (CMRX)
    • Harmony Biosciences Holdings Inc (HRMY)
    • Regeneron Pharmaceuticals Inc (REGN)
    • Selecta Biosciences Inc (SELB)
    • Vir Biotechnology Inc (VIR)

ITeos Therapeutics Dividend Yield

Data Unavailable

ITeos Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: -88.75% 786.95%
Revenue: -77.59% 31.72%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 41.47
Upside from Last Price: 204.26%

Major Shareholders

  • How many ITOS shares are owned by institutional investors?
    52.7M ITOS shares are owned by institutional investors
  • How many ITOS shares are owned by insiders?
    94.4K ITOS shares are owned by insiders